For instance, the use of proteasome inhibitors such as bortezomib, which prevents the degradation of IκB (inhibitor of NF-κB), thus inhibiting NF-κB activation, has been found effective in treating multiple myeloma by reducing NF-κB mediated survival signals (Moreau et al., 2011). Here, NFKB1 is linked to plasma cell myeloma.